This content is machine translated Guselkumab Study success: application for admission to PsoA submitted New Phase III data from the DISCOVER-1 and DISCOVER-2 studies show improvement in joint and skin symptoms of psoriatic arthritis at week 52, and an indication expansion of guselkumab is...…
View Post 3 min This content is machine translated Guselkumab Now also available as a patient-friendly ready-to-use pen The device, which was recently approved by Swissmedic, enables psoriasis sufferers to self-administer the biologic in single doses. It is currently the only IL23 inhibitor available in Switzerland in the...…